Mantle-cell lymphoma
JO Armitage, DL Longo - New England Journal of Medicine, 2022 - Mass Medical Soc
Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …
historically been associated with a poor outcome, but survival is improving. The …
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
P Jain, ML Wang - American journal of hematology, 2022 - Wiley Online Library
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications
Tumor heterogeneity is a hallmark of cancer and one of the primary causes of resistance to
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …
Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world …
PURPOSE Commonly used first-line (1L) treatments for mantle cell lymphoma include high-
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
dose cytarabine-based induction followed by autologous stem-cell transplant (ASCT) for …
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study
Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-
treat population, where no standard therapy exists. We evaluated outcomes in patients with …
treat population, where no standard therapy exists. We evaluated outcomes in patients with …
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
Introduction: The therapeutic options for mantle cell lymphoma (MCL) include traditional
chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the …
chemo-immunotherapy for newly diagnosed cases, and targeted treatments including the …
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open …
AK Zoellner, M Unterhalt, S Stilgenbauer… - The Lancet …, 2021 - thelancet.com
Background Autologous haematopoietic stem-cell transplantation (HSCT) in first remission
is the current standard treatment in fit patients with mantle cell lymphoma. In this long-term …
is the current standard treatment in fit patients with mantle cell lymphoma. In this long-term …
Emerging therapies in mantle cell lymphoma
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin's lymphoma with highly
heterogeneous clinical presentation and aggressiveness. First-line treatment consists of …
heterogeneous clinical presentation and aggressiveness. First-line treatment consists of …
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) …
M Ladetto, S Cortelazzo, S Ferrero… - The Lancet …, 2021 - thelancet.com
Background Fit patients with mantle cell lymphoma aged 18–65 years are usually given
cytarabine and rituximab-based induction regimens followed by autologous haematopoetic …
cytarabine and rituximab-based induction regimens followed by autologous haematopoetic …